TGV-therapeutics is focused on the development of MYC-053, a novel and structurally distinct antifungal antibiotic, to treat various multidrug-resistant fungal infections.
MYC-053 represents a new chemical class of antifungal agents. It is not related to any of the three existing classes of antifungal agents, whose use is frequently characterized by cross-resistance.
MYC-053 possesses a unique dual mode of action against pathogenic fungi. It is designed to simultaneously inhibit chitin synthasesynthesis, which produces chitin, an essential component of the fungal cell wall, and nucleic acid synthesis in fungi.
MYC-053, a lead clinical candidate, is developed as an oral agent for the treatment of different fungal infections, including life-threatening invasive fungal infections caused by Candida glabrata, Candida auris, Cryptococcus spp., and Pneumocystis spp.
TGV-Therapeutics presented poster presentations on MYC-053 in vitro activity against key fungal pathogens commonly causing life-threatening infections at ASM Microbe 2017(1-5 June 2017, New Orleans, LA).